To evaluate the prognostic value of biomarkers of meningioma patients, we performed a meta-analysis of at least two or more studies of the association between 11 biomarkers (PR, cyclin A, TOP2A, p21, MCM6, H3k27me3, Bcl-2, p53, VEGF, PHH3, and Ki-67/MIB-1) and their respective prognostic outcomes using the univariate or multivariate HR and 95% CI by forest plot of random-effects model. The gene discussed is CCNA2; the disease is meningioma.